Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Karus Therapeutics has entered into a research collaboration with The Babraham Institute targeting inflammatory diseases such as rheumatoid arthritis.
Subscribe to our email newsletter
Collaboration will focus on studying phosphatidylinositol-3-kinases (PI3K) inhibitors, which regulate PI3K family of enzymes that plays a vital role in immune cell function.
One of the collaboration leads at the Babraham Institute Dr Phillip Hawkins said that in vivo studies revealed that PI3K-p110ß and PI3K-p110d targeting is a successful way to treat rheumatoid arthritis in small animal models.
"By working with Karus, we gain unique access to scientific leadership in the field of PI3K inhibitor design and development," Hawkins added.
PI3K signalling and the immune response, particularly the role of the different isoforms of the PI3K catalytic subunit p110, PI3K-p110ß and PI3K-p110d, on neutrophil cell function will be further analyzed.
The Babraham Institute director Professor Michael Wakelam said, "The understanding of the PI3K pathway brought about in particular by many years of BBSRC-supported fundamental research in the Stephens/Hawkins lab has been critical in informing a number of companies, including Karus, in their aim to develop novel therapeutics."
Financial terms of the deal were not revealed.